Wafaa Mamilli will join Roche as the company's new Chief Digital Technology Officer in February. This follows expansive roles she has held at Zoetis and at Eli Lilly.
With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...
Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been making waves in the healthcare sector with its groundbreaking treatments for ...
Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.
Many Americans support prohibiting commercials for prescription drugs on television. But enacting that ban could be ...
The recent U.S. Food and Drug Administration approval for Eli Lilly and Co.'s Omvoh, a new therapy to treat Chron's disease ...
Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span ...
As more United States drug price changes have come to light this month, it remains clear that companies are tamping down ...
An analyst thinks he has cracked the code on why highflying Eli Lilly missed two quarters of Wall Street projections.
Investigative therapies to treat moderate to severe plaque psoriasis in clinical trials include several orally administered ...
The Growing Market for Weight Loss Treatments: Innovation, Patents, and the Future of GLP-1 Agonists
In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and ...
Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback